Durack patients benefit from $80M investment in eye medication from 1 November
November 13, 2018
Federal Member for Durack and Minister for the Environment Melissa Price said the Morrison Government will invest $80 million in eye medications through the Pharmaceutical Benefits Scheme (PBS), helping those living in the Durack electorate improve and preserve their vision.
Minister Price said from 1 November 2018, patients will get new subsidised treatment options for a range of eye conditions.
The medication Ozurdex® is being listed for the treatment of blocked veins in the retina due to a condition known as retinal vein occlusion, which leads to varying degrees of vision loss.
“This medicine will benefit patients in Durack who would normally pay around $5,000 a year for this treatment or more than $1,350 per script,” the Minister said.
“Under the PBS they will pay a maximum of $39.50 per script, with concessional patients, including pensioners, paying just $6.40.”
In addition, the current PBS listing for the medication Lucentis® will be expanded for patients suffering a condition that is associated with unwanted growth of new blood vessels in the eye that impact vision and a type of extremely acute near-sightedness.
“Patients will be able to access this medicine, which would normally cost up to $7,000 a year, for maximum of $39.50 per script, with concessional patients paying only $6.40,” said Minister Price.